The Europe Interventional Cardiology Devices Market would witness market growth of 7.0% CAGR during the forecast period (2023-2030). In the year 2020, the Europe market's volume surged to 11,480.1 thousand units, showcasing a growth of 7.0% (2019-2022).
Bioresorbable stents, which gradually dissolve after they have served their purpose, are gaining traction. These stents are designed to address some of the long-term limitations of traditional stents, such as the risk of restenosis and the need for long-term antiplatelet therapy. There is a surge in structural heart procedures, which involve repairing or replacing damaged heart valves without open-heart surgery. Transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR) are notable procedures in this category. Advanced imaging technologies, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), have been integrated into interventional cardiology procedures. These technologies provide real-time, high-resolution images to guide interventions with greater precision.
Advancements in genetics and biomarker identification have allowed for more personalized treatment plans. Tailoring interventions to a patient's unique genetic makeup and risk factors has become more common. The shift towards value-based healthcare has prompted providers to focus on patient outcomes and cost-effectiveness. This has led to a more critical evaluation of the efficacy and cost-effectiveness of interventional cardiology procedures and devices.
Cardiovascular diseases, including coronary artery disease, heart attacks, and heart failure, remain a leading cause of morbidity and mortality in Europe. The high prevalence of CVDs drives the demand for interventional cardiology procedures and devices. Europe has one of the world's largest aging populations. The expansion of the European interventional cardiology devices market is driven by the region's high disease burden, advanced healthcare infrastructure, regulatory framework, clinical expertise, and commitment to improving cardiovascular care. As Europe continues to invest in healthcare infrastructure and technology, the demand for interventional cardiology devices is expected to grow further, offering new opportunities for improving patient outcomes and advancing cardiovascular care. All these factors will uplift the regional market expansion in the coming years.
The Germany market dominated the Europe Interventional Cardiology Devices Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,390.7 million by 2030. The UK market is exhibiting a CAGR of 6% during (2023 - 2030). Additionally, The France market would experience a CAGR of 7.8% during (2023 - 2030).
Based on End-use, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers & Others. Based on Product, the market is segmented into Coronary Stents (Drug Eluting Stents, Bare Metal Stents, Bioabsorbable Stents), Accessory Devices (PTCA Guidewires, Diagnostic Catheters, PTCA Guiding Catheters, Introducer Sheaths), PTCA Balloon Catheters (Normal, Specialty, Drug Coated), Intravascular Imaging Catheters & Pressure Guidewires. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Interventional Cardiology Devices Market will Hit $21.9 Billion by 2030, at a CAGR of 7.4%
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Terumo Corporation, Medtronic PLC, B. Braun Melsungen AG, Biotronik SE & Co. KG, Cardinal Health, Inc., Teleflex, Inc., Koninklijke Philips N.V., Alvimedica.
By End Use (Volume, Thousand Units, USD Million, 2019-2030)
By Product (Volume, Thousand Units, USD Million, 2019-2030)
By Country (Volume, Thousand Units, USD Million, 2019-2030)
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 